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Surveillance of amantadine and oseltamivir resistance 
among influenza viruses was begun in Hong Kong in 2006. 
In  2008,  while  both A/Brisbane/59/2007-like  and A/Hong 
Kong/2652/2006-like viruses (H1N1) were cocirculating, we 
detected amantadine and oseltamivir resistance among A/
Hong Kong/2652/2006-like viruses (H1N1), caused by ge-
netic reassortment or spontaneous mutation. 
A 
high rate of oseltamivir resistance in seasonal influen-
za virus A (H1N1) infection was reported in Europe in 
the winter of 2007–08 (1). Of subtype H1N1 isolates tested 
in 18 European countries, 59 (13.5%) of 437 were resis-
tant to oseltamivir and carried the substitution of histidine 
by tyrosine at residue 274 (H274Y) of the neuraminidase 
(NA) gene. Genetic analysis showed that all oseltamivir-
resistant strains of subtype H1N1 virus remained suscep-
tible to amantadine.
In Hong Kong Special Administrative Region, Peo-
ple’s Republic of China, amantadine and oseltamivir are 
not commonly used to treat patients with influenza. Sur-
veillance of amantadine and oseltamivir resistance among 
influenza viruses was begun in 2006 after a high rate of 
amantadine resistance was reported among subtype H3N2 
viruses (2) and a stockpile of oseltamivir was purchased 
for pandemic preparedness. Oseltamivir resistance was first 
detected in January 2008. We report detection of subtype 
H1N1 virus isolates that became resistant to amantadine 
and oseltamivir because of genetic reassortment and spon-
taneous mutation.
The Study
As part of ongoing surveillance, respiratory samples 
are routinely collected from patients seeking treatment with 
respiratory illness in clinics and hospitals of Hong Kong. 
Virus isolation is performed according to a standard pro-
tocol (3). From January 2006 through June 2008, a total of 
827 influenza viruses (H1N1) were tested for oseltamivir 
resistance by an enzyme inhibition assay (NA-STAR; Ap-
plied Biosystems, Foster City, CA, USA) or by nucleotide 
sequencing of the NA gene to detect the H274Y mutation. 
The isolates were also tested for resistance to amantadine 
by an in-house–designed PCR (protocol available on re-
quest) and nucleotide sequencing of the matrix (M2) gene 
segment. A 575-nt fragment of the NA gene and a 199-nt 
fragment of the M2 gene were amplified by the designed 
primers N1–1H and N1–2H, and MA 692 and MA 891 
(available on request), respectively, and sequenced by us-
ing a Genetic Sequencer 3100 or 3130XL (Applied Biosys-
tems). Sequences obtained were aligned by using Simmon-
ics (4) and analyzed by MEGA version 2.1 (5). Increasing 
amantadine resistance, from 107 (48.0%) of 223 isolates 
in 2006 to 12 (85.7%) of 14 in 2007, was associated with 
clade 2C A/Hong Kong/2652/2006-like viruses (6); none 
were resistant to oseltamivir.
A  subtype  H1N1  virus  resistant  to  oseltamivir,  but 
sensitive to amantadine, was first detected in Hong Kong 
in January 2008, which coincided with the emergence of 
clade 2B A/Brisbane/59/2007-like viruses. From January 
through June 2008, 87 (12.5%) of 697 isolates tested were 
resistant to oseltamivir. They all carried the H274Y muta-
tion in the NA gene and showed an ≈1,000-fold reduction in 
susceptibility to oseltamivir (50% inhibitory concentration 
values increased from 0.5 nmol/L to 500 nmol/L). Analysis 
of the M2 genes showed that 3 (3.4%) of 87 oseltamivir-
resistant isolates also carried the S31N mutation associated 
with amantadine resistance. These 3 viruses were isolated 
from 2 infants and an elderly woman in different hospi-
tals during 2008 (March, April, and June, respectively). To 
eliminate the possibility of mixed strains, we designed a 
real-time PCR using single nucleotide polymorphisms to 
detect antimicrobial drug–susceptible strains (with S31 and 
H274) and drug resistant strains (with S31N and H274Y) in 
the samples (method available on request). Results showed 
that the 3 isolates did not possess S31 and H274.
To further study the genetic mechanism of emergence 
of antiviral drug resistance among subtype H1N1 viruses, 
we performed nucleotide sequencing on a partial segment 
of the hemagglutinin (HA) gene on 84 (97%) of 87 oselta-
mivir-resistant and 37 (5%) of 697 oseltamivir-susceptible 
viruses isolated in our laboratory in 2008. PCR and DNA 
sequencing of the HA gene were carried out by using the 
primers H1–1 and H1–2, which flank a fragment of 612 nt 
of the HA segment (7). Sequences were obtained from 121 
virus isolates (Table).
Of 37 oseltamivir-susceptible viruses, analysis of the 
HA, NA, and M2 genes showed that 20 were susceptible to 
amantadine and similar to the clade 2B A/Brisbane/59/2007 
virus (GenBank accession no. CY030232) (8). Fourteen 
were similar to clade 2C A/Hong Kong/2652/2006 virus 
(GenBank  accession  no.  CY031342),  an  amantadine-re-
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sistant virus isolated in our laboratory in 2006 which re-
mained prevalent in Hong Kong in 2007 and 2008. Three 
isolates had HA and NA genes similar to those of clade 2B 
but carried an amantadine-resistant M2 gene similar to that 
of the A/Hong Kong/2652/2006 virus.
Among 84 oseltamivir-resistant strains, 81 remained 
susceptible to amantadine and had HA and M2 genes simi-
lar to those of clade 2B A/Brisbane/59/2007 virus but car-
ried a single point mutation H274Y in the NA gene. The 
other 3 isolates were resistant to oseltamivir and amanta-
dine; they had similar HA and M2 genes to those of clade 
2C  A/Hong  Kong/2652/2006  virus  but  had  the  H274Y 
mutation in their NA gene. One of the viruses had an NA 
gene similar to that of the oseltamivir-resistant clade 2B 
A/Brisbane/59/2007 virus, whereas the other 2 viruses had 
NA genes similar to those of amantadine-resistant clade 2C 
A/Hong Kong/2652/2006 virus (Figure). These results sug-
gest that the 3 isolates acquired amantadine and oseltamivir 
resistance by different mechanisms. A clade 2C A/Hong 
Kong /942/2008 virus acquired an NA gene carrying the 
H274Y mutation by reassortment with an oseltamivir-re-
sistant clade 2B virus; the other 2 clade 2C viruses, A/Hong 
Kong /1052/2008 and A/Hong Kong /1313/2008, acquired 
oseltamivir resistance through a spontaneous H274Y muta-
tion in the NA gene.
To study the effect of the resistant gene on the replica-
tion efficiency of the viruses, we conducted experiments us-
ing amantadine- and oseltamivir-resistant viruses in MDCK 
cells. Briefly, we placed in quadruplicate on MDCK cells 
one 50% tissue culture infectious dose per 0.1 mL of sub-
type H1N1 viruses with different antiviral drug–resistance 
patterns  (amantadine-resistant  only,  oseltamivir-resistant 
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Table. Phylogenetic analysis of HA, NA, and M2 genes of influenza viruses A (H1N1) with different drug-resistance characteristics
isolated in Hong Kong, January–June 2008* 
Characteristics No. isolates HA clade  NA clade  M2 clade  Mutation
Oseltamivir resistant (n = 84) 
  Amantadine susceptible  81 2B† 2B 2B H274Y in NA 
  Amantadine resistant  1 2C† 2B 2C H274Y in NA, S31N in M2 
2 2C 2C 2C H274Y in NA, S31N in M2 
Oseltamivir susceptible (n = 37) 
  Amantadine susceptible  20 2B 2B 2B None
  Amantadine resistant  14 2C 2C 2C S31N in M2 
3 2B 2B 2C S31N in M2 
*HA, hemagglutinin; NA, neuraminidase; M2, matrix.  
†Clade 2B or clade 2C indicates the gene specified has a nucleotide homology >99% to that of A/Brisbane/59/2007 or A/Hong Kong/2652/2006 virus, 
respectively. 
Figure. Phylogenetic analysis of the hemagglutinin gene (A), neuraminidase gene (B), and matrix gene (C) of influenza virus (H1N1). 
The 3 clade 2C viruses with double resistance are indicated by circles, the 3 clade 2B viruses with amantadine resistance are indicated 
by triangles, and A/Brisbane/59/2007 and A/Hong Kong/2652/2006 are indicated by squares. Scale bars indicate 0.5% difference in 
nucleotide sequence.only, amantadine- and oseltamivir-resistant, and amanta-
dine- and oseltamivir-susceptible), incubated the cultures 
at 33°C, and examined the cytopathic effect (CPE) daily 
for 7 days. By observing the timing of CPE appearance and 
relative progressive rate of CPE, we found no substantial 
difference in growth efficiency and similar replication pat-
terns for the 4 different types of subtype H1N1 strains.
Conclusions
Reassortment  of  gene  segments  likely  occurred 
among  clade  2B  and  clade  2C  subtype  H1N1  viruses 
while they were cocirculating in Hong Kong. Clade 2B A/
Brisbane/59/2007-like viruses also were cocirculating with 
clade 2C A/Hong Kong /2652/2006-like viruses in about 
the  same  proportion  during  the  2008  influenza  season. 
We identified 3 clade 2B A/Brisbane/59/2007-like viruses 
(isolated from 1 outbreak) that were oseltamivir-sensitive 
in  their  HA  and  NA  genes  but  carried  an  amantadine-
resistant M2 gene that was similar to clade 2C A/Hong 
Kong/2652/2006 virus. We also identified 3 virus isolates 
that were resistant to both amantadine and oseltamivir. The 
HA, NA, and M2 gene sequences of the 3 oseltamivir- and 
amantadine-resistant subtype H1N1 isolates were depos-
ited in GenBank (accession nos. FJ227684–FJ227689 and 
FJ581446–FJ581448).
All 3 isolates were clade 2C A/Hong Kong/2652/2006-
like  viruses,  but  they  acquired  oseltamivir  resistance 
through spontaneous mutation or reassortment with a clade 
2B A/Brisbane/59/2007-like virus. Gene sequencing results 
confirmed that no epidemiologic link existed among the 3 
patients infected with these isolates.
Monitoring  of  antiviral  resistance  among  influenza 
isolates showed that resistance pattern changed among sub-
type H1N1 viruses when different lineages were introduced. 
While oseltamivir resistance appears to be largely confined 
to clade 2B viruses and amantadine resistance to clade 2C 
viruses, oseltamivir- and amantadine-resistant viruses due 
to spontaneous mutation or reassortment were detectable 
when clade 2B and 2C viruses were cocirculating. If antivi-
ral resistance markers are combined with sequence data of 
HA, NA, and M genes, systematic monitoring would make 
it possible to track the spread of influenza viruses globally 
and to clarify the underlying mechanism for the spread of 
such resistance. 
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